Loading....

Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according to results of a Phase 2b clinical trial. The study titled, “Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis […]

The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment of autoimmune diseases. Remicade is widely used for rheumatoid arthritis (RA) therapy. Biosimilars are biopharmaceutical drugs that have similar properties to other licensed therapies. Sandoz announced the […]

Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent study suggests. Results of the study, “Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Results of the TRACTION Randomized Controlled Trial,” were […]

Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable therapeutic index that is under development for the treatment of autoimmune inflammatory diseases like RA and psoriasis. It’s a new, first-in-class A3 adenosine receptor agonist (A3AR). […]